Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of Ofatumumab SC in Pemphigus Vulgaris
NCT02613910Phase 3Terminated
- Sponsor
- GSK
- Start
- Dec 2015
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ofatumumab in pemphigus vulgaris (PV), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events and AEs Leading to Permanent Discontinuation, Number of Participants With Severe Adverse Events and 9 more. Started Dec 2015; status: terminated.
02
Drugs
ofatumumab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT02613910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02613910.